Does the novel 5-lipoxygenase inhibitor ABT-761 attenuate cerebral vasospasm in a rabbit model of subarachnoid hemorrhage?
The results demonstrated that ABT-761 is effective in attenuating experimental cerebral vasospasm, indicating that this new drug represents a potential therapeutic agent for the treatment of vasospasm after SAH.
The progression-free rates confirm that cetuximab q2w in combination with irinotecan is an option, and is as active and safe as the standard weekly regimen.